Effects of the N/L‐Type Calcium Channel Blocker Cilnidipine on Nephropathy and Uric Acid Metabolism in Hypertensive Patients With Chronic Kidney Disease (J‐ CIRCLE Study)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of the N/L‐Type Calcium Channel Blocker Cilnidipine on Nephropathy and Uric Acid Metabolism in Hypertensive Patients With Chronic Kidney Disease (J‐ CIRCLE Study)

Published:2014-09-29 Issue:10 Volume:16 Page:746-753
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J Clin Hypertens

Author:

Uchida Shunya¹,Takahashi Masato²,Sugawara Masahiro³,Saito Tomoaki⁴,Nakai Kazuhiko⁵,Fujita Masami⁶,Mochizuki Koichi⁷,Shin Isu⁸,Morita Takashi⁹,Hikita Tomoyuki¹⁰,Itakura Hironao¹¹,Takahashi Yuko¹²,Mizuno Shigeki¹³,Ohno Yasumi¹⁴,Ito Kageki¹⁵,Ito Takafumi¹⁶,Soma Masayoshi¹⁷

Affiliation:

1. Internal Medicine Teikyo University School of Medicine Tokyo Japan

2. Takahashi Clinic Tokyo Japan

3. Sugawara Clinic Tokyo Japan

4. Itabashi Medical Association Hospital Tokyo Japan

5. Nakai Clinic Tokyo Japan

6. Fujita Clinic Tokyo Japan

7. Mochizuki Internal Medicine Clinic Tokyo Japan

8. Sekimachi Internal Medicine Clinic Tokyo Japan

9. Morita Clinic Tokyo Japan

10. Hikita Clinic Tokyo Japan

11. Kusunoki Clinic Tokyo Japan

12. Miyazono Internal Medicine Clinic Tokyo Japan

13. Mizuno Clinic Tokyo Japan

14. Ohno Internal Medicine Clinic Tokyo Japan

15. Ito Internal Medicine & Pediatrics Clinic Tokyo Japan

16. Nephrology Shimane University Tokyo Japan

17. General Medicine Nihon University School of Medicine Tokyo Japan

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.12412

Reference35 articles.

1. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization

2. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

3. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease

4. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

5. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of cilnidipine-loaded self-micro-emulsifying drug delivery system (SMEDDS) by quantification of comparative pharmacokinetic parameters using validated LC-ESI-MS/MS bioanalytical method and pharmacodynamic assessment;Annales Pharmaceutiques Françaises;2024-07

2. A Comprehensive Insight on Pharmacological Properties of Cilnidipine: A Fourth-generation Calcium Channel Blocker;Cardiovascular & Hematological Agents in Medicinal Chemistry;2024-03

3. Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications;Mayo Clinic Proceedings;2022-07

4. Dihydropyridine calcium channel blockers for the renoprotective therapy of hypertensive patients with chronic kidney disease;Nephrology (Saint-Petersburg);2021-02-13

5. Comparison of Usage Patterns and Outcomes by Dual Type Calcium Channel Blockers in Patients with Chronic Kidney Disease;Korean Journal of Clinical Pharmacy;2020-12-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3